Loading…

The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan

Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis....

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1997-05, Vol.57 (9), p.1625-1629
Main Authors: SEED, M. P, BROWN, J. R, FREEMANTLE, C. N, PAPWORTH, J. L, COLVILLE-NASH, P. R, WILLIS, D, SOMERVILLE, K. W, ASCULAI, S, WILLOUGHBY, D. A
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1629
container_issue 9
container_start_page 1625
container_title Cancer research (Chicago, Ill.)
container_volume 57
creator SEED, M. P
BROWN, J. R
FREEMANTLE, C. N
PAPWORTH, J. L
COLVILLE-NASH, P. R
WILLIS, D
SOMERVILLE, K. W
ASCULAI, S
WILLOUGHBY, D. A
description Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78971882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78971882</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-46e765177b18627298ca6223fe8d595c5834d6c7f98da1e4e10f61d51c8090ee3</originalsourceid><addsrcrecordid>eNo9kEtLxDAUhYMo4zj6E4Qs1F0lSfNcyuALBtyM65Imt9NIm4xNK8y_t2BxcbgczseBe87QmopSF4pzcY7WhBBdCK7YJbrK-Wu2ghKxQitDS26MXKO0bwGH2IY6jCFFnBrsUpdiwSS2HmJydnAhpt5iDz_QpWMPccQ2-lmHkA4QIYeM6xMe0zE422EfXJcaiNbNxZg9invcnmw3DSnaeI0uGttluFnuBn2-PO-3b8Xu4_V9-7QrWib1WHAJSgqqVE21ZIoZ7axkrGxAe2GEE7rkXjrVGO0tBQ6UNJJ6QZ0mhgCUG_Tw13sc0vcEeaz6kB10nY2QplwpbRTVms3g7QJOdQ--Og6ht8OpWhaa87slt3n-rhlsdCH_Y0xKxjUpfwHhKm-t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78971882</pqid></control><display><type>article</type><title>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>SEED, M. P ; BROWN, J. R ; FREEMANTLE, C. N ; PAPWORTH, J. L ; COLVILLE-NASH, P. R ; WILLIS, D ; SOMERVILLE, K. W ; ASCULAI, S ; WILLOUGHBY, D. A</creator><creatorcontrib>SEED, M. P ; BROWN, J. R ; FREEMANTLE, C. N ; PAPWORTH, J. L ; COLVILLE-NASH, P. R ; WILLIS, D ; SOMERVILLE, K. W ; ASCULAI, S ; WILLOUGHBY, D. A</creatorcontrib><description>Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 9134996</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adenocarcinoma - drug therapy ; Administration, Topical ; Animals ; Antineoplastic agents ; Apoptosis - drug effects ; Biological and medical sciences ; Cell Survival - drug effects ; Chemotherapy ; Colonic Neoplasms - drug therapy ; Cyclooxygenase Inhibitors - administration &amp; dosage ; Diclofenac - administration &amp; dosage ; Hyaluronic Acid - administration &amp; dosage ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mitosis - drug effects ; Neovascularization, Pathologic - prevention &amp; control ; Pharmaceutical Vehicles ; Pharmacology. Drug treatments ; Platelet Endothelial Cell Adhesion Molecule-1 - analysis</subject><ispartof>Cancer research (Chicago, Ill.), 1997-05, Vol.57 (9), p.1625-1629</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2662480$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9134996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SEED, M. P</creatorcontrib><creatorcontrib>BROWN, J. R</creatorcontrib><creatorcontrib>FREEMANTLE, C. N</creatorcontrib><creatorcontrib>PAPWORTH, J. L</creatorcontrib><creatorcontrib>COLVILLE-NASH, P. R</creatorcontrib><creatorcontrib>WILLIS, D</creatorcontrib><creatorcontrib>SOMERVILLE, K. W</creatorcontrib><creatorcontrib>ASCULAI, S</creatorcontrib><creatorcontrib>WILLOUGHBY, D. A</creatorcontrib><title>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Administration, Topical</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cell Survival - drug effects</subject><subject>Chemotherapy</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Cyclooxygenase Inhibitors - administration &amp; dosage</subject><subject>Diclofenac - administration &amp; dosage</subject><subject>Hyaluronic Acid - administration &amp; dosage</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mitosis - drug effects</subject><subject>Neovascularization, Pathologic - prevention &amp; control</subject><subject>Pharmaceutical Vehicles</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Endothelial Cell Adhesion Molecule-1 - analysis</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLxDAUhYMo4zj6E4Qs1F0lSfNcyuALBtyM65Imt9NIm4xNK8y_t2BxcbgczseBe87QmopSF4pzcY7WhBBdCK7YJbrK-Wu2ghKxQitDS26MXKO0bwGH2IY6jCFFnBrsUpdiwSS2HmJydnAhpt5iDz_QpWMPccQ2-lmHkA4QIYeM6xMe0zE422EfXJcaiNbNxZg9invcnmw3DSnaeI0uGttluFnuBn2-PO-3b8Xu4_V9-7QrWib1WHAJSgqqVE21ZIoZ7axkrGxAe2GEE7rkXjrVGO0tBQ6UNJJ6QZ0mhgCUG_Tw13sc0vcEeaz6kB10nY2QplwpbRTVms3g7QJOdQ--Og6ht8OpWhaa87slt3n-rhlsdCH_Y0xKxjUpfwHhKm-t</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>SEED, M. P</creator><creator>BROWN, J. R</creator><creator>FREEMANTLE, C. N</creator><creator>PAPWORTH, J. L</creator><creator>COLVILLE-NASH, P. R</creator><creator>WILLIS, D</creator><creator>SOMERVILLE, K. W</creator><creator>ASCULAI, S</creator><creator>WILLOUGHBY, D. A</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</title><author>SEED, M. P ; BROWN, J. R ; FREEMANTLE, C. N ; PAPWORTH, J. L ; COLVILLE-NASH, P. R ; WILLIS, D ; SOMERVILLE, K. W ; ASCULAI, S ; WILLOUGHBY, D. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-46e765177b18627298ca6223fe8d595c5834d6c7f98da1e4e10f61d51c8090ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Administration, Topical</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cell Survival - drug effects</topic><topic>Chemotherapy</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Cyclooxygenase Inhibitors - administration &amp; dosage</topic><topic>Diclofenac - administration &amp; dosage</topic><topic>Hyaluronic Acid - administration &amp; dosage</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mitosis - drug effects</topic><topic>Neovascularization, Pathologic - prevention &amp; control</topic><topic>Pharmaceutical Vehicles</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Endothelial Cell Adhesion Molecule-1 - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SEED, M. P</creatorcontrib><creatorcontrib>BROWN, J. R</creatorcontrib><creatorcontrib>FREEMANTLE, C. N</creatorcontrib><creatorcontrib>PAPWORTH, J. L</creatorcontrib><creatorcontrib>COLVILLE-NASH, P. R</creatorcontrib><creatorcontrib>WILLIS, D</creatorcontrib><creatorcontrib>SOMERVILLE, K. W</creatorcontrib><creatorcontrib>ASCULAI, S</creatorcontrib><creatorcontrib>WILLOUGHBY, D. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SEED, M. P</au><au>BROWN, J. R</au><au>FREEMANTLE, C. N</au><au>PAPWORTH, J. L</au><au>COLVILLE-NASH, P. R</au><au>WILLIS, D</au><au>SOMERVILLE, K. W</au><au>ASCULAI, S</au><au>WILLOUGHBY, D. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>57</volume><issue>9</issue><spage>1625</spage><epage>1629</epage><pages>1625-1629</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo. colon-26 tumor growth was preceded by angiogenesis and reduced apoptotic and mitotic indices. Diclofenac reduced proliferation and viability in vitro, and stimulated apoptosis. Hyaluronan inhibited proliferation and viability at 1 mg/ml but was inactive below this level. Topical application of diclofenac inhibited tumor prostaglandin synthesis and retarded angiogenesis and tumor growth (ratio of treatment:control, 0.174). The mitotic index remained unaltered in vivo, whereas the apoptotic index and necrosis were increased. Topical vehicle exhibited slight antitumor and antiangiogenesis activity. The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit antitumor activity in similar fashion to those seen in vitro and explain its clinical efficacy.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9134996</pmid><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1997-05, Vol.57 (9), p.1625-1629
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_78971882
source EZB-FREE-00999 freely available EZB journals
subjects Adenocarcinoma - drug therapy
Administration, Topical
Animals
Antineoplastic agents
Apoptosis - drug effects
Biological and medical sciences
Cell Survival - drug effects
Chemotherapy
Colonic Neoplasms - drug therapy
Cyclooxygenase Inhibitors - administration & dosage
Diclofenac - administration & dosage
Hyaluronic Acid - administration & dosage
Medical sciences
Mice
Mice, Inbred BALB C
Mitosis - drug effects
Neovascularization, Pathologic - prevention & control
Pharmaceutical Vehicles
Pharmacology. Drug treatments
Platelet Endothelial Cell Adhesion Molecule-1 - analysis
title The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T12%3A59%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20inhibition%20of%20colon-26%20adenocarcinoma%20development%20and%20angiogenesis%20by%20topical%20diclofenac%20in%202.5%25%20hyaluronan&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=SEED,%20M.%20P&rft.date=1997-05-01&rft.volume=57&rft.issue=9&rft.spage=1625&rft.epage=1629&rft.pages=1625-1629&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E78971882%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h268t-46e765177b18627298ca6223fe8d595c5834d6c7f98da1e4e10f61d51c8090ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78971882&rft_id=info:pmid/9134996&rfr_iscdi=true